ERBB2 and aneurysmal bone cyst: Although a number of individual prognostic factors have been associated with therapeutic outcomes in HER2-positive ABC patients (8–11), there are no validated clinical risk prediction tools applicable to HER2-positive ABC patients being considered for first-line pertuzumab, trastuzumab, and docetaxel treatment.